Colgan Stephen M, Mukherjee Som, Major Pierre
Department of Medicine, Juravinski Cancer Center, Hamilton, Ontario.
Clin Colorectal Cancer. 2007 Mar;6(6):442-6. doi: 10.3816/CCC.2007.n.014.
The aim of this review is to discuss the basic science of tumor angiogenesis and recent clinical trial results with angiogenic inhibitors. Colorectal cancer (CRC) continues to be a major cause of all new cancer cases and cancer-related deaths in North America. Although advances in chemotherapy have increased overall survival for patients suffering from metastatic CRC, the survival rate continues to be poor. In order to develop new and more effective therapies for advanced CRC, it is important to understand the basic biologic processes that govern tumor growth. This review will focus on pathways involved in stimulating tumor growth and angiogenesis. Recent excitement has been generated by the clinical efficacy of targeted antiangiogenic therapy against growth factors important in angiogenesis and tumor proliferation. By presenting the basic biology of tumor growth and angiogenesis, we will attempt to explain the therapeutic effects of different angiogenesis inhibitors and speculate how combination treatments with these agents might be beneficial.
本综述的目的是讨论肿瘤血管生成的基础科学以及血管生成抑制剂的近期临床试验结果。在北美，结直肠癌（CRC）仍然是所有新增癌症病例和癌症相关死亡的主要原因。尽管化疗取得了进展，转移性CRC患者的总生存率有所提高，但生存率仍然很低。为了开发针对晚期CRC的更新、更有效的疗法，了解控制肿瘤生长的基本生物学过程非常重要。本综述将聚焦于刺激肿瘤生长和血管生成的相关途径。针对血管生成和肿瘤增殖中重要的生长因子进行靶向抗血管生成治疗的临床疗效，引发了近期的关注。通过介绍肿瘤生长和血管生成的基础生物学，我们将试图解释不同血管生成抑制剂的治疗效果，并推测这些药物的联合治疗可能如何有益。
